Psychiatric University Hospital, Universität Rostock, Medizinische Fakultät, Neurochemisches Labor der Klinik für Psychiatrie and Psychotherapie, Rostock, Germany.
Neurochem Res. 2010 Sep;35(9):1376-83. doi: 10.1007/s11064-010-0194-3. Epub 2010 Jun 4.
Polyunsaturated Fatty acids (PUFAs) seem to be helpful in the therapy of depression. Zinc (Zn) may be one co-factor contributing to their antidepressive effect. Zn acts lipid protective and is a constituent of fatty acid metabolism enzymes. In animals, an antidepressive effect of Zn was already demonstrated. Therefore, if and how Zn and PUFAs correlate in depressive patients or in individuals from the general population was investigated. Blood samples were collected from 88 depressive in-patients and 88 volunteers from the general population matched for age-group and gender (each 32 men and 56 women, 21-70 years) for measurement of Zn (colorimetric) and of 12 fatty acids (FAs) (by capillary gas-chromatography). Severity of depression in patients was assessed by Beck Depression Inventory (BDI) and Hamilton Depression Rating Scale (HDRS). Zn concentration was independent of age, gender and body-mass-index and significantly correlated with the severity of depression measured by BDI (r = 0.26; P = 0.034) in depressive patients,. HDRS was inversely correlated with gammalinolenic acid concentration (r = -0.24; P = 0.029). Median serum Zn concentration in depressive patients did not differ from control individuals. Zn was correlated with myristic acid concentration (r = 0.22; P < 0.05) in controls from the general population; and a negative correlation between Zn and dihomogammalinolenic acid concentration (r = -0.26; P < 0.05) was found in depressive inpatients. FA composition in serum significantly differed between depressive and healthy persons: Depressive patients had higher stearic and arachidonic acid (AA) concentration. Relative to AA, their eicosapentaenoic and docosapentaenoic acid concentration were diminished compared to the general populations group. These results do not confirm the hypothesis of a general lack of Zn in depressive disorders, but Zn concentrations differed dependent on comorbid disorders and severity of depression. In depressive patients and control persons Zn concentration is associated with different FAs indicating diverging metabolic pathways.
多不饱和脂肪酸(PUFAs)似乎对抑郁症的治疗有帮助。锌(Zn)可能是其抗抑郁作用的一个辅助因素。Zn 具有脂质保护作用,是脂肪酸代谢酶的组成部分。在动物中,Zn 已经表现出抗抑郁作用。因此,研究了抑郁患者或一般人群中 Zn 和 PUFAs 之间的相互关系。从 88 名住院抑郁症患者和 88 名年龄和性别相匹配的一般人群志愿者(每组 32 名男性和 56 名女性,年龄 21-70 岁)中采集血样,用于测量 Zn(比色法)和 12 种脂肪酸(FA)(毛细管气相色谱法)。患者的抑郁严重程度通过贝克抑郁量表(BDI)和汉密尔顿抑郁量表(HDRS)评估。Zn 浓度与年龄、性别和体重指数无关,与抑郁症患者的抑郁严重程度呈显著正相关(BDI,r = 0.26;P = 0.034)。HDRS 与γ-亚麻酸浓度呈负相关(r = -0.24;P = 0.029)。抑郁症患者的血清 Zn 浓度中位数与对照组无差异。Zn 与一般人群对照组中的肉豆蔻酸浓度呈正相关(r = 0.22;P <0.05);在住院抑郁症患者中,发现 Zn 与二同型-γ-亚麻酸浓度呈负相关(r = -0.26;P <0.05)。血清中 FA 组成在抑郁症患者和健康人之间存在显著差异:抑郁症患者的硬脂酸和花生四烯酸(AA)浓度较高。与 AA 相比,他们的二十碳五烯酸和二十二碳五烯酸浓度与一般人群组相比有所降低。这些结果并未证实抑郁症患者普遍缺乏 Zn 的假设,但 Zn 浓度因合并症和抑郁严重程度而异。在抑郁症患者和对照组中,Zn 浓度与不同的 FA 相关,表明代谢途径不同。